Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vertex Pharmaceuticals (NQ: VRTX ) 499.88 +27.08 (+5.73%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Vertex Pharmaceuticals < Previous 1 2 3 4 5 6 7 8 9 ... 53 54 Next > 2 Top Growth Stocks to Buy Right Now and Hold Forever April 28, 2024 These healthcare stocks can provide enviable long-term portfolio growth. Via The Motley Fool Want $1 Million in Retirement? 3 Stocks to Buy Now And Hold for Decades. April 27, 2024 These three should have a lot of room to run. Via The Motley Fool $100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management Drugs April 26, 2024 Unlock Vertex Pharmaceuticals' pioneering treatments, from the groundbreaking Trikafta for cystic fibrosis to the promising non-opioid painkillers. Via Benzinga (VRTX) - Analyzing Vertex Pharmaceuticals's Short Interest April 25, 2024 Via Benzinga 2 Fantastic Growth Stocks to Buy Right Now April 25, 2024 Don't overlook these high-growth businesses. Via The Motley Fool Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon. April 24, 2024 Good news could be just around the corner for two drugmakers not named Novo Nordisk. Via The Motley Fool If You Invested $1000 In This Stock 10 Years Ago, You Would Have $6,000 Today April 16, 2024 Via Benzinga The Analyst Landscape: 16 Takes On Vertex Pharmaceuticals April 12, 2024 Via Benzinga Vertex Pharmaceuticals: Buy, Sell, or Hold? April 11, 2024 The stock hasn't made for a great buy this year, but is Vertex worth investing in for the long run? Via The Motley Fool Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy? April 23, 2024 Vertex is broadening its portfolio. Via The Motley Fool Making Sense of Amazon CEO Andy Jassy's Latest Letter April 22, 2024 And that's just part of the interesting news for investors to dig into. Via The Motley Fool If You'd Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, Here's How Much You'd Have Today April 22, 2024 Could Vertex's growth story continue? Via The Motley Fool Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now April 22, 2024 These stocks could be near major inflection points. Via The Motley Fool 2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever April 20, 2024 These stocks probably won't be getting much cheaper. Via The Motley Fool 3 Relatively Safe Growth Stocks You Can Buy and Hold April 20, 2024 Low risk and high-reward potential? These stocks could offer both. Via The Motley Fool 3 Biotech Stocks Set to Double by 2028 April 20, 2024 These are three of the top biotech stocks set to double by 2028. Add them to your portfolio to maximize your potential gains. Via InvestorPlace Is Vertex Pharmaceuticals Stock a Millionaire Maker? April 19, 2024 Does this pharma stock have the potential to turn a $25,000 investment into seven figures or more? Via The Motley Fool Tesla To $123? Here Are 10 Top Analyst Forecasts For Thursday April 18, 2024 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy? April 18, 2024 The biotech just added another potential growth driver to its pipeline. Via The Motley Fool Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain April 18, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock April 15, 2024 Vertex just laid claim to an asset that might be very valuable. Via The Motley Fool Could This Stock Be the Next Biotech Buyout? April 13, 2024 Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease. Via The Motley Fool Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review April 12, 2024 The stock market gave some bullish signs, with Nvidia rebounding, but the indexes generally fell for the week on inflation and Mideast fears. Via Investor's Business Daily Topics Economy Exposures Interest Rates Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact April 11, 2024 Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth... Via Benzinga Stocks Bounce Back With Tech, Gold Gaining After Modest Producer Inflation Data: What's Driving Markets Thursday? April 11, 2024 Investors can breathe a sigh of relief on Thursday as last month’s Producer Price Index (PPI) inflation turned out slightly lower than expected, albeit with some caveats across different measures... Via Benzinga Topics Economy Exposures Interest Rates Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024 April 11, 2024 In a stock picker’s market, here are three biotech stocks analysts believe have a chance to outperform the market in 2024. Via InvestorPlace Raymond James Just Raised Its Price Target on Nvidia (NVDA) Stock April 11, 2024 Nvidia stock is on the move Thursday after shares of NVDA got an increased price target of $1,100 from Raymond James analysts. Via InvestorPlace Apple Spyware Warning: What to Know About ‘Mercenary Spyware Attack’ Alerts April 11, 2024 An Apple spyware warning has been sent to iPhone owners in 92 states as they have been targeted by a mercenary spyware attack. Via InvestorPlace The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today April 11, 2024 Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease. Via InvestorPlace Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options April 11, 2024 Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options. Via Investor's Business Daily < Previous 1 2 3 4 5 6 7 8 9 ... 53 54 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
